ATAI
mental health disorders have become one of global health burdens depression rates of us adults saw a increase since the onset of the covid pandemic as a response to the technical risks associated with drug development focuses on compound classes with prior evidence in humans and utilizes a decentralized drug development process active programs drug and discovery programs and enabling technologies focusing on potentially disease modifying therapies validation of operating model of compass pathways and validating license deal between perception we have a strong cash position of as of june and access to up to from term loan facility with giving cash runway into life sciences healing so that everyone everywhere can live more life | ATAI
Company
Deck Type
Sector
Industry
Deck date
November 2022
Slide
3 of 36
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
October 2022
mental health disorders have become one of global health burdens depression rates of us adults saw a increase since the onset of the covid pandemic as a response to the technical risks associated with drug development focuses on compound classes with prior evidence in humans and utilizes a decentralized drug development process active programs drug and discovery programs and enabling technologies focusing on potentially disease modifying therapies validation of operating model of compass pathways and validating license deal between perception we have a strong cash position of as of june and access to up to from term loan facility with giving cash runway into life sciences healing so that everyone everywhere can live more life | ATAI
Investor Presentation
September 2022
mental health disorders have become one of global health burdens depression rates of us adults saw a increase since the onset of the covid pandemic as a response to the technical risks associated with drug development focuses on compound classes with prior evidence in humans and utilizes a decentralized drug development process active programs drug and discovery programs and enabling technologies focusing on potentially disease modifying therapies validation of operating model of compass pathways and validating license deal between perception we have a strong cash position of as of june and access to up to from term loan facility with giving cash runway into life sciences healing so that everyone everywhere can live more life | ATAI
Investor Presentation
June 2020
mental health disorders have become one of global health burdens depression rates of us adults saw a increase since the onset of the covid pandemic as a response to the technical risks associated with drug development focuses on compound classes with prior evidence in humans and utilizes a decentralized drug development process active programs drug and discovery programs and enabling technologies focusing on potentially disease modifying therapies validation of operating model of compass pathways and validating license deal between perception we have a strong cash position of as of march with runway into life sciences healing so that everyone everywhere can live more life | ATAI
Related slides by other companies
23andMe
Investor Presentation
April 2023
the program is a prime example of the value brings to drug discovery and development | 23andMe
BenevolentAI
Results
March 2023
is a leading enabled drug discovery development company with a platform generated pipeline discovery development industry leading platform uncovers novel biology across diseases and drug modalities portfolio of in class and best in class programs discovered using our proprietary platform discovery preclinical clinical expansive knowledge graph with multimodal data foundations disease and drug modality agnostic generate predictions with the aim to increase the probability of success asset in phase assets in platform generated drug programmes enabled | BenevolentAI
Gatos Silver
Results
November 2023
highlights strong cash flows and increased production guidance strong balance sheet cash balance of at debt free robust operating and financial results at continued strong cash flow generation clear pathway to further mine life extension and growth increased full year and production guidance mine life extended to end capital efficient margin improvement and expansion options | Gatos Silver
Genetron
Results
June 2022
in drug development services for i a | Genetron
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io